The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

Pfizer Inc. (NYSE: PFE) is navigating a period of strategic upheaval and legal scrutiny as it ends its clinical collaboration ...

Pfizer Inc. closed 25.65% short of its 52-week high of $31.54, which the company achieved on July 30th.

COVID-19 tweets from November 2020 have come back to haunt Pfizer once again. | COVID-19 tweets from November 2020 have come ...

Allan Small of Allan Small Financial Group at iA Private Wealth is buying names he used to consider too expensive ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

The House Judiciary Committee revealed Thursday that Pfizer’s former Global Head of Vaccines Research and Development, Dr.

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...